Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before Delivery
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- Respiratory syncytial virus (RSV) vaccination at least five weeks prior to delivery results in the highest transplacental transfer of maternal antibodies to the neonate, according to a study published online Nov. 6 in the American Journal of Obstetrics & Gynecology.
Olyvia J. Jasset, from the Vincent Center for Reproductive Biology at Massachusetts General Hospital in Boston, and colleagues examined how gestational age at vaccination and time elapsed from maternal RSV vaccination to delivery impacts transfer of maternal antibodies measured in the umbilical cord at delivery and in peripheral blood of infants aged 2 months in a prospective cohort study enrolling 124 individuals who received the RSV vaccination during pregnancy.
The researchers found that compared with natural infection, maternal RSV vaccination resulted in significantly higher maternal and cord anti-RSV F antibody levels. Significantly lower cord:maternal transfer ratios were seen in association with maternal vaccination two to three and three to four weeks prior to delivery versus more than five weeks prior to delivery; similarly, for pertussis vaccination administered prior to 30 weeks of gestation, transfer ratios were significantly lower at two to three or three to four versus more than four weeks prior to delivery.
"The finding of optimal transplacental transfer of maternal antibody at ≥5 weeks postvaccination may inform future evaluations of vaccine timing," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility
MONDAY, April 7, 2025 -- Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published...
COVID-19 Linked to More Severe Outcomes Than Flu, RSV in 2022-2023 Season
THURSDAY, Jan. 30, 2025 -- COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season, according...
Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season
WEDNESDAY, Jan. 8, 2025 -- Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.